First Patient Dosed With LIXTE's LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating With NKI, Supported by Major Pharma Company
Express News | First Patient Dosed With Lixte’s Lb-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating With Nki, Supported by Major Pharma Company
Express News | Lixte Biotechnology Provides Update on Recent Activities and Developments
LIXTE Biotechnology Holdings to Present at Two Investor Conferences
10-Q: Q2 2024 Earnings Report
Express News | Lixte Biotechnology Holdings Announces Collaboration on a New Colon Cancer Clinical Trial